BFT reduces amyloid aggregates, decreases tau levels, and activates the phosphorylation of glycogen synthase kinase-3α and 3β (GSK-3α/β), leading to attenuation of its activity in AD transgenic mice (Pan et al., 2010). The gene discussed is MAPT; the disease is Alzheimer disease.